DGK

DGK

Diacylglycerol Kinase (DGK) regulates the equilibrium between phosphatidic acid (PA) and DAG. DAG is phorylated by DGK to produce PA. Ten mammalian DGK subtypes (-) that can be divided into five different types exist. Each subtype has its own tissue distribution. Among them, the production of DAG as a second messenger following stimulation of the T cell receptor is specifically regulated by DGK and DGK. However, in T cells, DGK is the predominant isoform. Certain DGK isoforms that are dysregulated cause DAG-activated PKC, attenuated insulin signaling, and dysregulated glucose metabolism. DGK participates in a variety of physiological processes, such as cell migration and proliferation, glucose uptake, immunity, and the development of neuronal networks.

DGK related products

Structure Cat No. Product Name CAS No. Product Description
V32186 (5Z,2E)-CU-3 1815598-71-0 (5Z,2E)-CU-3is a novel, potent and selective diacylglycerol kinase alpha (DGKalpha) inhibitorwithanIC50valueof0.6 μM, attenuating cancer cell proliferation and simultaneously enhancing immune responses including anti-cancer immunity.
V73996 AMB639752 371210-26-3 AMB639752 is a potent DGKα inhibitor.
V73987 BAY 2965501 2732902-08-6 BAY 2965501 is a potent and specific diacylglycerol kinase zeta (DGKζ) inhibitor.
V51059 BAY-2965501 DGKzeta inhibitor
V74001 BMS-332 2407892-15-1 BMS-332 is a dual (bifunctional) inhibitor of DGKα/ζ lipokinase with IC50 of 0.005 μM (DGKα) and 0.001 μM (DGKζ) respectively.
V73995 BMS-496 2407854-31-1 BMS-496 is a dual (bifunctional) inhibitor of DGKα/ζ lipokinase with IC50 of 0.09 μM (DGKα) and 0.006 μM (DGKζ) respectively.
V73988 BMS-502 2407854-18-4 BMS-502 (Compound 22) is a potent dual (bifunctional) inhibitor of diacylglycerol kinase (DGK) α and ζ with IC50s of 4.6 nM and 2.1 nM.
V73997 BMS-684 313552-29-3 BMS-684 is a selective DGKα inhibitor (antagonist) with IC50 of 15 nM.
V73999 Cochlioquinone A (Luteoleersin) 32450-25-2 Cochlioquinone A is an ATP-competitive diacylglycerol kinase inhibitor (Ki= 3.1 μM).
V73989 DGK-IN-1 2407892-34-4 DGK-IN-1 is a T cell activator from patent WO2020006018A1, Example 25.
V74000 DGKα&ζ-IN-1 2830643-06-4 DGKα&ζ-IN-1 (Compound II) is a DGK target inhibitor.
V73993 DGKα-IN-2 2648556-92-5 DGKα-IN-2 (example 48) is a DGKα inhibitor (antagonist) with IC50 of 0.9 nM, found in patent WO2021105115.
V73994 DGKα-IN-3 2648418-86-2 DGKα-IN-3 (example 25) is a DGKα inhibitor (antagonist) with IC50 of 283 nM, found in patent WO2021105115.
V74003 DGKα-IN-4 2648723-43-5 DGKα-IN-4 (example 432) is a DGKα inhibitor (antagonist) with IC50 of 0.1 nM, found in patent WO2021105117.
V74002 DGKα-IN-6 2886734-91-2 DGKα-IN-6 is a DGKα inhibitor (antagonist) with IC50 of 1.377 nM, found in patent WO2022271650 (compound 143).
V73992 DGKα-IN-7 2886092-50-6 DGKα-IN-7 is a DGKα inhibitor (antagonist) with IC50 of 6.225 nM, found in patent WO2022271684 (compound 100).
V73998 DGKζ-IN-1 2660218-70-0 DGK z-IN-1 (compound 9) is an inhibitor (blocker/antagonist) of DGKz.
V74004 DGKζ-IN-4 2778366-77-9 DGKζ-IN-4 is a DGKζ inhibitor.
V86113 DGKζ-IN-5 2951002-04-1
Contact Us Back to top